Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

 

PDF Download Buy Article Permissions and Reprints

Summary

In order to evaluate the effects of hypocholesterolemic drugs on plasma fibrinogen concentration, six groups of subjects with primary hypercholesterolemia have been put on treatment with diet alone or diet plus fenofibrate (100 mg t.i.d.), slow release bezafibrate (400 mg once a day), gemfibrozil (600 mg b.i.d.), simvastatin (20 mg once a day) or pravastatin (20 mg once a day) respectively. After 1 month of therapy, plasma fibrinogen significantly decreased by 9% and 15% in fenofibrate and bezafibrate groups respectively and increased by 19% in gemfibrozil treated patients. After 4 months of therapy the changes were −16% with fenofibrate, −10% with bezafibrate and +20% with gemfibrozil. No significant changes were observed in patients treated with diet alone, simvastatin or pravastatin. The fibrinogen lowering effect of fenofibrate and bezafibrate does not seem to be related to the hypolipidemic activity of the drugs.

• References

• 1 Kannel WB, Wolf PA, Castelli WP. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987; 258: 1183-1186
  CrossrefPubMedGoogle Scholar
• 2 Wilhelmsen L, Svaerdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-504
  CrossrefPubMedGoogle Scholar
• 3 Heinrich J, Schulte H, Balleisen L, Assmann G, Van de Loo J. Predictive value of haemostatic variables in the PROCAM-Study. Thromb Haemostas 1991; 65: 815
  PubMedGoogle Scholar
• 4 Handa K, Kono S, Arakawa K. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 1989; 77: 209-213
  CrossrefPubMedGoogle Scholar
• 5 Lowe GDO, Drummond MM, Lorimer AR, Hutton I, Forbes CD, Prentice CRM, Barbenel JC. Relation between extent of coronary artery disease and blood viscosity. Br Med J 1980; 1: 673-674
  PubMedGoogle Scholar
• 6 Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S, Miller GJ, North WRS, Stirling y, Thompson SG. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537
  PubMedGoogle Scholar
• 7 Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82: 19l6-1924
  CrossrefPubMedGoogle Scholar
• 8 Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipoproteinemias. Bull WHO 1970; 43: 891-908
  PubMedGoogle Scholar
• 9 Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haemat 1957; 17: 237-240
  CrossrefPubMedGoogle Scholar
• 10 Snedecor GW, Cochran WG. Statistical Methods. 6. Iowa State University Press: Ames, IA; 1967
  Google Scholar
• 11 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 19l-205
  PubMedGoogle Scholar
• 12 Ernst E. Plasma fibrinogen – an independent cardiovascular risk factor. J Intern Med 1990; 227: 365-372
  CrossrefPubMedGoogle Scholar
• 13 Owen J, Grossman BA, Palmer RH. Hyperlipidemia and in vivo hemostatic system activation. Semin Thromb Hemostas 1988; 14: 241-245
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Lowe GDO, Mc ArdleBM, Stromberg P, Lorimer AR, Forbes CD, Prentice CRM. Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipoproteinemia. Lancet 1982; ii: 472-474
  PubMedGoogle Scholar
• 15 Koppensteiner R, Minar E, Ehringer H. Effects of lovastatin on hemorheology in type II hyperlipoproteinemias. Atherosclerosis 1990; 83: 53-58
  CrossrefPubMedGoogle Scholar
• 16 Bo M, Bonino E, Nierotti M, Gottero M, Pernigotti L, Molaschi M, Fabris F. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 1991; 42: 106-113
  CrossrefPubMedGoogle Scholar
• 17 Jay RH, Rampling MW, Betteridge DJ. Abnormalities of blood rheology in familial hypercholesterolemia: effects of treatment. Atherosclerosis 1990; 85: 249-256
  CrossrefPubMedGoogle Scholar
• 18 Leschke M, Hoffken H, Schmidtsdorff A, Blanke H, Eybring R, Joseph K, Strauer BE. The effect of fenofibrate on fibrinogen concentration and blood viscosity: its possible consequences for myocardial microcirculation in coronary heart disease. Dtsch Med Wschr 1989; 114: 939-944
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Almer LD, Kjellstrom T. The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. Atherosclerosis 1986; 61: 81-85
  CrossrefPubMedGoogle Scholar
• 20 Niort G, Bulgarelli A, Pagano A. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988; 7l: 113-119
  PubMedGoogle Scholar
• 21 Avellone G, DiGarbo V, Panno AV, Cordovo R, Lepore R, Strano A. Changes induced by gemfibrozil on lipid, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int Angiol 1988; 7: 270-277
  PubMedGoogle Scholar
• 22 Agrati AM, Ambrosi G, Ferraro G. Gemfibrozil efficacy vs pantetine in dyslipoproteinemic patients: a controlled study. Curr Ther Res 1989; 45: 650-663
  PubMedGoogle Scholar
• 23 O’Brien JR, Etherington MD, Shuttleworth RD, Adams CM, Middleton JE, Goodland FC. A pilot study on the effect of gemfibrozil on some haematological parameters. Thromb Res 1982; 26: 275-279
  CrossrefPubMedGoogle Scholar
• 24 Schwartzkopff W, Menzel B, Stern K. Gemfibrozil in patients with primary hyperlipoproteinemias. Therapiewoche 1985; 35: 1388-1389
  PubMedGoogle Scholar
• 25 Stringer MD, Steadman CA, Kakkar VV. Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease. Some undiscovered actions. Curr Med Res Opin 1990; 12: 207-214
  CrossrefPubMedGoogle Scholar
• 26 Wilkes HC, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ. Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemostas 1992; 67: 503-506
  PubMedGoogle Scholar